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Abstract Daily consumption of seaweed has been proposed as
a factor in explaining lower postmenopausal breast cancer (BC)
incidence and mortality rates in Japan. This clinical trial
assessed the impact of introducing seaweed- to non-seaweed-
consuming American postmenopausal women. Fifteen healthy
postmenopausal women were recruited for a 3-month single-
blinded placebo controlled clinical trial; five had no history of
BC (controls) and ten were BC survivors. Participants ingested
ten capsules daily (5 g day−1) of placebo for 4 weeks, seaweed
(Undaria) for 4 weeks, then placebo for another 4 weeks. Blood
and urine samples were collected after each treatment period.
Urinary human urokinase-type plasminogen activator receptor
concentrations (uPAR) were analyzed by ELISA, and urine and
serum were analyzed for protein expression using surface-
enhanced laser desorption/ionization–time-of-flight mass
spectrometry (SELDI-TOF-MS). Urinary creatinine stan-
dardized uPAR (in pg mL μg−1 creatinine) changed signif-
icantly between groups, decreasing by about half following
seaweed supplementation (placebo 1, 1.5 (95 % CI, 0.9–
2.1) and seaweed, 0.9 (95 % CI, 0.6–1.1) while placebo 2
returned to pre-seaweed concentration (1.7 (95 %CI, 1.2-2.2);
p00.01, ANOVA). One SELDI-TOF-MS-identified urinary
protein (m/z 9,776) showed a similar reversible decrease with
seaweed and is reported to be associated with cell attachment.
One serum protein (m/z 8,928) reversibly increased with
seaweed and may be the immunostimulatory complement
activation C3a des-arginine. uPAR is higher among postmen-
opausal women generally, and for BC patients, it is associated
with unfavorable BC prognosis. By lowering uPAR, dietary
seaweed may help explain lower BC incidence and mortality
among postmenopausal women in Japan.
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Introduction
The relationship between the relative breast cancer (BC) risk
and seaweed intake among humans is only now unfolding. A
small body of research, both in vivo and in vitro, suggests
seaweed may be useful in BC prevention (Funahashi et al.
1999; Teas et al. 1984; Yamamoto et al. 1987). Seaweeds are
specifically used to treat tumors in Traditional Chinese Med-
icine and Japanese folk medicine. On a population level, those
people for whom seaweed is a regular part of their diet, most
notably in Japan, have dramatically lower rates of BC (Hebert
and Rosen 1996; Kodama et al. 1991).
Epidemiologic studies done in Japan in the 1980s, before
Westernized diets were common, reported that Japanese wom-
en had one out of three the rate of premenopausal BC and one
out of nine the rate of postmenopausal BC (Reddy et al. 1980).
Even today, BC incidence rates for women in Japan are 20/
100,000 compared with the US average of 118/100,000 (US
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Cancer Statistics Working Group 2007). Although genetic
predisposition has been proposed, when rates among migrants
from Japan to the USA are compared, BC incidence almost
doubles after 10 years of residence in the USA (20/100,000 to
35/100,000) (Shimizu et al. 1991) and continues to increase
with each successive generation (LeMarchand et al. 1985).
Japanese–American women who develop BC have signifi-
cantly better survival rates than other American ethnic groups
(Kanemori and Prygrocki 2005). On the other hand, Asian–
American women over 50 years of age living in Los Angeles,
especially Japanese–American women, have one of the most
rapidly increasing BC incidence rates (Deapen et al. 2002).
These data support the hypothesis that lifestyle changes and
possibly gene–nutrient interactions are important in BC
susceptibility.
Seaweed is a typical part of East-Asian diets, although
consumption varies widely among individuals (Fukuda et al.
2007). Brown seaweeds have no land equivalents in terms
of their specific components of fiber (alginate), primary
carotenoid (fucoxanthin), sulfated polysaccharide (fucoidan
and laminarin), and polyphenol defense compounds, each of
which has been reported to have strong anti-cancer activity
(Kang et al. 2012; Kotake-Nara et al. 2005; Koyanagi et al.
2003; Miao et al. 1999; Son et al. 2003).
Many in vivo and in vitro studies of dietary seaweed report
decreased angiogenesis and increased apoptosis of tumor cells
(Konishi et al. 2006; Koyanagi et al. 2003; Sekiya et al. 2005),
inhibition of tumor cell adhesion and metastasis (Liu et al.
2005), and enhanced immune responses (Maruyama et al.
2006). Although Nishino et al. (2000) have investigated sea-
weed activation of the urokinase plasminogen system path-
way, urokinase-type plasminogen activator receptor (uPAR)
was not specifically studied. Based on the wide range of
antitumor effects, we investigated the possibility that seaweed
could affect uPAR concentrations in women who consume
seaweed. The uPAR (CD87), is the membrane receptor for
serine protease and is central to plasminogen activation and
pericellular proteolysis. uPAR is an extracellular receptor
involved in multiple signaling pathways important in main-
taining homeostasis, directly interacting with 42 proteins,
affecting the extracellular matrix (ECM), cell adhesion, in-
flammation, immune function (complement) activation, blood
coagulation, and tissue repair (Eden et al. 2011). Increased
concentrations have been shown to be associated with the
presence of cancer, and increased cell surface shedding of
uPAR is characteristic of more rapid cancer progression
(Boonstra et al. 2011). We therefore included evaluation of
uPAR as a possible biomarker for seaweed activity that might
be related to BC prevention.
To further assess whether a dietary seaweed intervention
could alter protein expression in urine and serum in a non-
seaweed-consuming population of healthy postmenopausal
women, we used surface-enhanced laser desorption/
ionization–time of flight coupled with mass spectrometry
(SELDI-TOF-MS). Proteomic analyses have been used to
identify cancer biomarkers with high sensitivity and specific-
ity, including those related to BC (Gast et al. 2009; van
Winden et al. 2009). SELDI has also been shown to be
sensitive enough to be used to identify changes in serum
associated with the addition of a novel food (green tea) (Tsu-
neki et al. 2004).
Materials and methods
Study population The Human Subjects Research Review
Board of the US Army Medical Research and Materiel
Command, the Palmetto Hospital Health Alliance (Colum-
bia, SC), and the University of South Carolina Institutional
Review Boards approved the study (IRB number, 99-104).
The clinical study registration number is NCT01663792.
Consent forms were reviewed verbally, and all participants
gave written informed consent.
Inclusion criteria were: being healthy, postmenopausal
(verified by follicle stimulating hormone (FSH; 23.0–116
mIU mL−1)), no allergies to seaweed, soy, shellfish or iodine;
no current use of tobacco; no hormone replacement therapy
or, for BC survivors, no chemotherapy or radiation treatments
within the preceding 6 months and no history of cancer (other
than BC or squamous cell skin cancer) within the previous
20 years; no current gastrointestinal disorders or diabetes; and
omnivorous eating habits (including meat and dairy products
more than twice per week), limit alcoholic intake to ≤1 drink
(12 g alcohol)/week, and no oral antibiotics taken in the
previous 3 months. Women agreed to eat their normal diet,
avoiding seaweeds and to continue their habitual use of med-
ications, vitamins, and supplements during the study.
Women were recruited through the Palmetto Health Tumor
Registry, the South Carolina Comprehensive Breast Center
registry, and the Psychosocial Oncology patient database of
women who had indicated their interest in participation in BC
research projects and had signed consent forms giving per-
mission to be contacted. Once contacted, if eligible for study,
the woman was mailed an Informed Consent form along with
a confirmation letter of her scheduled appointment. Three
women dropped out of the study after the initial contact but
before commencing the study, leaving 15 healthy postmeno-
pausal women. All 15 were mammographically negative for
BC; five had never been diagnosed for BC (Controls), five had
been treated for early (stages 0, I, or II) estrogen receptor-
positive BC (ER+), and five had been treated for early estro-
gen receptor negative BC (ER−). Diagnosis of estrogen re-
ceptor status was confirmed by the treating physician.
Study design This single-blinded placebo-controlled study
incorporated a 1-month placebo run in period (P1) followed
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by a 1-month treatment with seaweed (S) followed by a 1-
month placebo washout period (P2). Identical capsules filled
with maltodextrin were used as placebo. All participants
ingested 5 g day−1 of the allocated treatment in ten 500-
mg capsules.
Adherence to protocol At each clinic visit, women were
asked about any significant health changes, including new
medications or alcoholic beverages consumed. Urinary io-
dine was used to confirm adherence to the protocol during
seaweed supplement period.
Seaweed and placebo Undaria pinnatifida (Harvey) Surin-
gar (Japanese wakame) is one of the most popular dietary
seaweeds eaten in Japan and Korea (Maruyama et al. 2003).
The U. pinnatifida was harvested by Soriano from the Bahia
Bustamante cove on the Patagonian coast of Argentina. We
only used the sporophylls (Japanese mekabu), known to
contain the highest amount of fucoidan (8 %; Soriano
S.A., personal communication). Fucoidan is one of the
water soluble components of seaweed that has shown high
antitumor effects studies (Cumashi et al. 2007).
A 5-g serving of Undaria contained 21 kJ, 0.5 g protein,
0.4 g fat, 0.06 g carbohydrate, 2.55 g fiber, 269.6 mg
potassium, and 153.2 mg sodium (Soriano 2008). Maltodex-
trin (Corn Products, Westchester, IL) was used as placebo,
and 5 g/day provided 84 kJ.
Encapsulation Undaria was tested for Escherichia coli,
Salmonella, Staphylococcus aureus, Pseudomonas aeruginosa,
all of which were non-detectable, yeast and mold, aerobic
recount, and moisture, met all safety standards (Proanalsis
S.A. and Food Control S.A. Argentina). The seaweed was
milled to a 300-μm powder (done on site at Gaiman by Soriano
S.A., Argentina). Both the maltodextrin and seaweed were
encapsulated into identical brown gelatin capsules (Vicofer,
Argentina).
Samples collection Blood samples were drawn from fasting
participants between 0630 and 1030 by venipuncture using
SST vacutainer tubes. The blood was allowed to clot at 4 °C
for 30 min, and then centrifuged at 1,500 rcf for 10 min
before being aliquoted into 1 mL tubes. First morning urine
samples were collected on the day of each clinic visit and
aliquoted into 1 mL tubes (200 μL each). All samples were
stored at −80 °C until analyses.
Laboratory analyses The Iodine Research Laboratory, De-
partment of Endocrinology, Diabetes and Nutrition, Boston
University School of Medicine analyzed the capsules for
iodine content.
Iodine in urine, empty capsules, and finished capsules
was analyzed using the ceritic-arsenic redox reaction.
Samples were analyzed according to standard determination
of total iodine protocol as outlined previously (Benotti et al.
1965). This used the reduction–oxidation reaction between
ceritic and arsenite catalyzed by iodine. The iodine concen-
tration was proportional to its catalytic activity. First, iodine
was precipitated with perchloric acid, and the samples were
digested with chloric acid. They were then measured spec-
trometrically at 420 nm (Autoanalyzer, Technicon Instru-
ment, Inc). Calculations were based on an iodine standard
curve. The urine results were calculated as μg of iodine dL−1
g−1 of creatinine.
Serum samples were analyzed for FSH at the Palmetto
Health Richland Hospital Core Laboratory in Columbia, SC
using standard direct chemiluminescent technology.
Urinary uPAR was analyzed at the University of South
Carolina Cancer Research Center using uPAR immunoassay
kit according to the manufacturer directions (R&D Systems,
Minneapolis, USA, cat No. DUP00). The optical density
was determined using a microtiter plate reader set at 450 nm
(Packard SpectraCount, USA).
SELDI-TOF-MS analysis: serum sample preparation Sam-
ples were thawed and then prepared by adding 180 μL of
denaturing buffer (8 M urea, 2 % CHAPS, 50 mM Tris,
pH 9) to 20 μL of serum then vortexed for 30 min at 4 °C
and diluted in 100 mM ammonium acetate (pH 4, 1:10)
binding buffer. Fifteen microliters of sample was added to
each spot and incubated for 1 h followed by a series of
washes with binding buffer and deionized H2O. Sinapinic
acid (SPA) was applied and arrays were analyzed.
Urine sample preparation Samples were thawed and vor-
texed briefly and then centrifuged at 10,000 rcf for 5 min at
4 °C. 160 μL of each sample was mixed with 60 μL of
denaturing buffer (8 M urea, 2 % CHAPS, 50 mM Tris,
pH 9) in 1.5 mL tubes then vortex and incubated for 30 min
at 4 °C. The pH was then set to 4.0 using NH4OH and H3PO4.
SELDI CM10 (weak cation exchange) chip was then equili-
brated with 100-μL binding buffer (100 mM NH4Oac) and
shook for 5 min. Sample mix (200 μL) was then combined
with 200-μL binding buffer and vortexed briefly. Binding
buffer was then discarded from chips and 190-μL sample
mix/binding buffer was added to two spots for replication.
Chips were then covered with Parafilm and shaken for 1 h.
The samples were then removed from chips, washed three times
with 100-μL binding buffer and shaken for 5 min before they
were washed twice with 100 μL ddH2O, shook for 2 min and
air dried. That was followed by applying 1μL energy absorbing
material (SPA) then dried twice. The chips were finally light
protected until analysis.
SELDI-TOF-MS analysis Samples were analyzed at the Mo-
lecular Epidemiology and Toxicology Laboratory at the
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University of California, Berkeley. CM10 ProteinChip arrays
were purchased from Ciphergen Biosystems (Fremont) and
prepared as described elsewhere (Hegedus et al. 2005) and
then analyzed using SELDI-TOF-MS ProteinChip Reader
(Series PBSII, Ciphergen Biosystems) with laser intensity
setting of 200 (arbitrary units), and detector sensitivity at 8,
collecting peak data at every five positions along the spot
surface. Mass spectra were generated in the m/z range of
1,500–25,000. The m/z value for each of the peaks was
determined using external calibration with known standards
using [Arg8]-vasopressin (1,084.25+1H), somatostatin
(1,637.9+1H), dynorphin A [209–225] (porcine; 2,147.5+
1H), ACTH [1–24] (human; 2,933.5+1H), insulin B-chain
(bovine; 3,495.94+1H), insulin (human recombinant;
5,807.65+1H), and hirudin (recombinant; 6,963.52+1H).
The Ciphergen Express (Ciphergen Biosystems) software col-
lected peak data, and each peak was analyzed according to the
following parameters: first pass of 5, second pass of 2, 0.8 %
peak width named same peak, and 25 % min−1 all spectra.
Statistical analysis Simple descriptive statistics were used to
characterize the study sample. Our statistical models used all
available data without imputation, allowing us to use the stan-
dard intention-to-treat approach (Rothman 1998). To test the
main study hypotheses, a repeated measures analysis of vari-
ance (ANOVA) was conducted using repeated measures
ANOVA (GraphPad Prism 5) with Tukey’s multiple compari-
son tests to determine differences between treatment groups.
Statistical analysis clusters were generated by Ciphergen Pro-
tein Chip Software Version 3.1 (Bio-Rad) from 1.5 to 25 kDa
with the following settings: first-pass signal-to-noise ratio (S/N)
of 5, second-pass S/N of 2, minimum peak threshold of 25 %,
and a cluster mass window of 0.8 %. Statistical analysis was
performed using the same software. Only m/z values signifi-
cantly different from the background are reported. All samples
were analyzed in duplicates. Individuals in each group of sub-
jects (control, ER+, or ER−) were paired for analysis by group
then by treatment arm (P1, S, and P2). Mann–Whitney U test
was applied to generate p values. Analysis of variance was used
to compare health and demographic variables. A p value of 0.05
was considered significant.
Results
Demographic variables for the study participants are pre-
sented (Table 1) and show no significant differences. The
health variables in Table 2 show cancer survivors had higher
screening FSH when compared with controls, indicating
possible hormonal differences. It was also notable that the
ER+ had lower BMI than the other two groups.
The iodine content in each 0.5 g capsule (n04) averaged
38.5 μg. Urinary iodine excretion standardized for creatinine
(in μg dL−1 g−1 of creatinine) increased slightly during sea-
weed supplementation, from 0.04 (95 % CI, 0.02–0.06) after
P1 to 0.05 (95 % CI, 0.03–0.06) on S returning to 0.03 (95 %
CI, 0.02–0.04) on P2, indicating adherence to the protocol, but
also that this low iodine-containing seaweed had little effect
on iodine metabolism. These trends were the same for women
taking thyroid hormone medication (n05) and those not tak-
ing thyroid medications (n010).
Urinary creatinine-standardized uPAR concentrations de-
creased by almost 50 % following seaweed supplementation
that was reversed after the second placebo treatment. The
uPAR concentrations (in pg mL μg−1 of creatinine) were P1,
1.5 (95 % CI, 0.9–2.1); S, 0.9 (95 % CI, 0.6–1.1); and P2,
1.7 (95 % CI, 1.2–2.2; p00.01, ANOVA). These trends were
observed in each group, regardless of BC history (Fig. 1).
The SELDI-MS-TOF data identified a total of 14 proteins
that were differentially expressed in serum (Fig. 2). Only
one serum protein reversibly changed in all three groups
with seaweed supplementation (m/z 8,927). Fewer urinary
proteins were identified using SELDI (Fig. 3), and only one
(m/z 9,776) showed a reversible response to seaweed, in-
creasing slightly, but significantly.
Discussion
We first proposed that seaweed intake could be a factor in
BC prevention in 1981 (Teas 1981), and although the evi-
dence from hundreds of research studies have supported
seaweed as important in a host of biological pathways.
Our study provides evidence that 5 g day−1 of brown sea-
weed (Undaria) stimulated significant changes in urinary
Table 1 Demographic variables for healthy postmenopausal women at
baseline compared by disease status
Control ER+ ER−
N 5 5 5







African American 2 0 4
European American 3 5 1
Education
High school 1 0 1
Some college or Technical degree 1 2 1
Bachelors or higher 3 3 3
Family income (annual)
$20–49,000 2 1 1
$50–99,000 2 1 3
>$100,000 1 2 0
Do not know 0 1 1
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uPAR and slight changes in two other proteins. For the
relatively small amount of seaweed (5 g day−1) to result in
a 50 % reduction in uPAR is remarkable. If supported in
other studies, it gives a clear mechanism for explaining the
various preventive and treatment-related effects of seaweed
supplementation. At the very least, it gives a plausible
mechanism for explaining the diverse findings of other
studies, which include cell adhesion and detachment from
the ECM of cancer cell leading to migration and metastasis
(Hildenbrand and Schaaf 2009).
In many ways, it is difficult to imagine how a mere 5 g
day−1 could have such a profound effect on systemic concen-
trations of uPAR and specific protein expression. One possi-
bility is that seaweed, like other dietary fibers, is known to
increase the mucus bilayer that protects the colonic mucosa,
stimulating mucus secretion and thickness (Brownlee et al.
2005). Other suggested consequences of dietary seaweed fiber
include increased stool bulk which would provide protection
from dietary toxins and carcinogens and reduction in amylase
activity leading to decreased glycemic response.
It is interesting that powdered seaweed (1 %, w/v) but not
seaweed extracts were responsible for almost 100 % inhibi-
tion of amylase and pepsin digestive enzyme activity in
vitro (Bobin-Dubigeon et al. 1997). Small water-soluble
molecules which would be lost in the production of seaweed
extracts were thought to be responsible for the inhibition of
protease activities. Thus, the small amount of dietary sea-
weed used in our study and consumed in Japan might be
expected to have a profound effect in humans.
Our study also provides a possible rationale for under-
standing why BC in non-seaweed-consuming Western pop-
ulations increases with age, but remains more or less stable
for Japanese women (Reddy et al. 1980). uPAR increases
after menopause (Chung et al. 1998), and if seaweed, on a
population level in Japan, has a significant impact on uPAR
concentrations, it may be the basis for the stable rates.
Our investigation using SELDI was interesting. Several
of proteins with high intensity have also been identified as
important in BC (Gast et al. 2009). uPAR has an m/z protein
size beyond the range we measured, but two proteins we
identified changed with seaweed. Serum protein (m/z 8,927)
has been identified as complement activation C3a des-
Table 2 Comparison of health variables for healthy postmenopausal women at baseline compared by disease status
Controls ER+ ER−
Screening FSH (mIU mL−1; 95 % CI) 57.4 (45.4, 69.4) a 72.5 (34.4, 110.7) b 78.3 (59.5, 97.1) b
Systolic blood pressure (mmHg; 95 % CI) 134.6 (119.3, 149.9) a 112.4 (97.6, 127.2) b 127.2 (114.9, 139.5) a
Diastolic blood pressure (mmHg; 95 % CI) 96.6 (87.1, 106.1) a 74.2 (63.5, 84.9) b 89.8 (82.0, 97.6) a
BMI (95 % CI) 34 (27, 41) a 24 (18, 30) b 32 (23, 41) a
BMI body mass index 0 weight (kg)/height (m)2
Different superscript letters within each column indicate significant differences between groups (p00.05; i.e., a vs. b is significant whereas a vs. a is not)
Fig. 1 Urinary uPAR concentrations compared by BC history and
treatment group (error bars indicate 95 % CI)
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arginine and may indicate stimulation of an immune re-
sponse that has also been detected in subjects with early
BC (Becker et al. 2004). In the seaweed literature, enhanced
immune function has been reported in vitro (Kim and Joo
2008) and in vivo (Kandasamy et al. 2012; Leonard et al.
2012). Increased expression of m/z 8,928 may be associated
with the observed enhanced immune function.
The urinary protein m/z 9,776 has not been identified as
important in BC but it has been identified as a hormone-
responsive protein important in decidualization of the endo-
metrial stromal matrix preceding embryo implantation (Oh
et al. 2008). This progesterone-responsive protein increased
with seaweed. In a study of conception rates in heat-stressed
cows, seaweed supplementation with a different brown sea-
weed (Ascophyllum) was associated with more than a 7-fold
increase in successful pregnancies (Kellogg et al. 2006).
This suggests that seaweed supplementation may influence
cell surface signaling receptors for steroid hormones.
As BC in Japan is characterized by higher rates of the more
favorable ER+ type, we anticipated that women with a history
of ER− BC might have different protein responses to dietary
seaweed. There were only minor differences in protein
expression by BC history, and possibly the variations might
reflect underlying differences in BC susceptibility. Further
research should be conducted to define whether or not these
minor differences reflect meaningful biological variations.
Seaweeds are consumed daily in Japan and are consid-
ered to be important in maintaining optimal health. The
actual amount of seaweed consumed is somewhat problem-
atic. Several different kinds of seaweed are eaten daily in a
variety of forms and dishes and are consumed dried in sushi
wrappers, fresh or rehydrated as a side dish, and used as
flavor condiments as well as the basis for broth-based
(dashi) flavoring added to other foods. It is therefore diffi-
cult to estimate the actual daily intake of seaweed. Our best
guess is that 5 g/day may approximate the mean Japanese
daily intake. A typical serving of the kind of seaweed used
in this study, wakame (Undaria), has been estimated at 1 g
by the Japanese Ministry of Health (Ministry of Health of
Japan 2004). Thus our study could overestimate the contri-
bution of Undaria to the average Japanese consumer, but as
a pilot study, we propose that it combines the mean dose of
seaweed and isolates a particular kind of seaweed, so the
effects we report can be attributed to one seaweed species.
Fig. 2 Comparison of
differentially expressed serum
proteins (m/z) and their relative
intensities by BC history and
treatment group
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Our primary reason for using whole seaweed rather than
a purified fraction is that people in Japan consume seaweed,
and it is this dietary preference that appears to be associated
with multiple health benefits (MacArtain et al. 2007). The
combination of various bioactive components in whole sea-
weed may be greater than the sum of the individual parts,
were they to be purified and tested individually. Many
previous in vitro and in vivo studies have used hot or cold
water extracts of Undaria, and have proposed that fucoidan,
a water-soluble sulfated polysaccharide primarily found in
brown seaweeds, as the most bioactive component
(Cumashi et al. 2007). In previous studies we have demon-
strated that Undaria fucoidan is absorbed by humans, despite
its large molecular size (Irhimeh et al. 2005). Although it
would be interesting to have used such an extract in our study,
it would have required obtaining approval to use the extract as
an Investigational New Drug, which would have taken exten-
sive and costly pretesting evaluation to register with the US
Food and Drug Administration. As an alternative, we chose to
use high-fucoidan seaweed, using only the sporophyll of
Undaria, collected at the peak of the summer harvest season.
These sporophylls consistently contain 8 % fucoidan/dry
weight and are also low in iodine (approximately 80 μg
g−1), and 5 g day−1 would be well under the tolerable upper
intake level of 1,100 μg/day (National Research Council
2001). In addition, no adverse effects have been recorded in
our previous studies using this 5 g day−1 dose of Undaria
sporophylls (Teas et al. 2009; Teas and Irhimeh 2012).
One of our study strengths was that it evaluated the intro-
duction of seaweed to a non-seaweed-consuming population,
Fig. 3 Comparison of
differentially expressed urine
proteins (m/z) and their relative
intensities by BC history and
treatment group
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and despite the women continuing with their normal diet,
significant changes in protein expression were observed. The
reversibility of the changes in the urinary concentration of
uPAR and of the two SELDI-identified proteins strongly
suggests the changes were attributable to the inclusion of
seaweed. As any small proof of principle study, our small
sample size was a limitation. However, finding significant
differences bodes well for future studies.
Data from uPAR concentration changes indicate that
seaweed affects ECM, which is known to influence cell
surface signaling, cell adhesion, and growth factor commu-
nication and responsiveness in breast tissue. Additional data
from SELDI proteomic analysis further supports the role of
seaweed supplementation in modulating proteins known to
affect cell adhesion, immune response, and inflammatory
responses. These effects may be mediated through the ECM
and be important in maintaining healthy structure and func-
tion in breast cells. In particular, lower uPAR concentrations
could reduce the likelihood of breast tissue transformation
and cancer cell proliferation and invasiveness.
The role of dietary seaweed in lowering uPAR may there-
fore be critical in explaining differences in postmenopausal
BC incidence and mortality between Japanese women and
women in other developed countries. The possibility that
dietary seaweed could decrease uPAR is especially important
in that there are no anti-uPAR drugs currently available
(Degryse 2011). Finding that seaweed can have a significant
effect on uPAR could be helpful both in designing future
drugs and dietary interventions for people with cancer.
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